Literature DB >> 14715048

Treatment of the metabolic disturbances caused by antipsychotic drugs: focus on potential drug interactions.

Trino Baptista1, N M K Ng Ying Kin, Serge Beaulieu.   

Abstract

The risk of excessive bodyweight gain, glucose dysregulation and hyperlipidaemia is differentially increased by conventional and atypical antipsychotic drugs. Switching or combining agents may be sufficient in some cases, but in many instances additional drug treatment will be required. This includes oral antidiabetics, insulin and agents to treat hyperlipidaemia, hypertension and platelet dysfunction, among others. Numerous pharmacokinetic and pharmacodynamic interactions with the antipsychotics are possible, although few have been tested in formal studies. After reviewing the literature, the authors provide preliminary guidelines to assist clinicians in drug selection for this complex and fragile clinical population.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14715048     DOI: 10.2165/00003088-200443010-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  97 in total

1.  Effect of amantadine on weight gain during olanzapine treatment.

Authors:  M Floris; J Lejeune; W Deberdt
Journal:  Eur Neuropsychopharmacol       Date:  2001-04       Impact factor: 4.600

2.  Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride.

Authors:  M Niemi; P J Neuvonen; K T Kivistö
Journal:  Clin Pharmacol Ther       Date:  2001-11       Impact factor: 6.875

3.  Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.

Authors:  M Niemi; J T Backman; M Neuvonen; J Laitila; P J Neuvonen; K T Kivistö
Journal:  Clin Pharmacol Ther       Date:  2001-04       Impact factor: 6.875

Review 4.  Tianeptine: a review of its use in depressive disorders.

Authors:  A J Wagstaff; D Ormrod; C M Spencer
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 5.  Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events.

Authors:  T Hatanaka
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

Review 6.  Rosiglitazone.

Authors:  J A Balfour; G L Plosker
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

Review 7.  Clinical pharmacokinetics of fibric acid derivatives (fibrates).

Authors:  D B Miller; J D Spence
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

8.  Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study.

Authors:  G L Zornberg; H Jick
Journal:  Lancet       Date:  2000-10-07       Impact factor: 79.321

Review 9.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 10.  Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience.

Authors:  Emilio Perucca
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

View more
  2 in total

Review 1.  Pharmacological management of atypical antipsychotic-induced weight gain.

Authors:  Trino Baptista; Yamily ElFakih; Euderruh Uzcátegui; Ignacio Sandia; Eduardo Tálamo; Enma Araujo de Baptista; Serge Beaulieu
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 2.  An overview of diabetes management in schizophrenia patients: office based strategies for primary care practitioners and endocrinologists.

Authors:  Aniyizhai Annamalai; Cenk Tek
Journal:  Int J Endocrinol       Date:  2015-03-23       Impact factor: 3.257

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.